Hans Starz
Overview
Explore the profile of Hans Starz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
228
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haggenmuller S, Wies C, Abels J, Winterstein J, Heinlein L, Nogueira Garcia C, et al.
Nat Commun
. 2025 Jan;
16(1):789.
PMID: 39824857
Accurate melanoma diagnosis is crucial for patient outcomes and reliability of AI diagnostic tools. We assess interrater variability among eight expert pathologists reviewing histopathological images and clinical metadata of 792...
2.
Kurz A, Krahl D, Kutzner H, Barnhill R, Perasole A, Fernandez Figueras M, et al.
Eur J Cancer
. 2023 Sep;
193:113294.
PMID: 37690178
Background: Historically, cancer diagnoses have been made by pathologists using two-dimensional histological slides. However, with the advent of digital pathology and artificial intelligence, slides are being digitised, providing new opportunities...
3.
Haggenmuller S, Maron R, Hekler A, Utikal J, Barata C, Barnhill R, et al.
Eur J Cancer
. 2021 Sep;
156:202-216.
PMID: 34509059
Background: Multiple studies have compared the performance of artificial intelligence (AI)-based models for automated skin cancer classification to human experts, thus setting the cornerstone for a successful translation of AI-based...
4.
Brinker T, Schmitt M, Krieghoff-Henning E, Barnhill R, Beltraminelli H, Braun S, et al.
J Am Acad Dermatol
. 2021 Feb;
86(3):640-642.
PMID: 33581189
No abstract available.
5.
Eigentler T, Assi Z, Hassel J, Heinzerling L, Starz H, Berneburg M, et al.
Oncotarget
. 2016 May;
7(24):36130-36137.
PMID: 27150060
Background: In patients with advanced melanoma the detection of BRAF mutations is considered mandatory before the initiation of an expensive treatment with BRAF/MEK inhibitors. Sometimes it is difficult to perform...
6.
Kretschmer L, Bertsch H, Zapf A, Mitteldorf C, Satzger I, Thoms K, et al.
Medicine (Baltimore)
. 2015 Sep;
94(36):e1433.
PMID: 26356697
Unlabelled: The objective of this study was to analyze different types of nodal basin recurrence after sentinel lymph node biopsy (SLNB) for melanoma. Patients And Methods: Kaplan-Meier estimates and the...
7.
Eigentler T, Schlaak M, Hassel J, Loquai C, Stoffels I, Gutzmer R, et al.
J Immunother
. 2014 Jul;
37(7):374-81.
PMID: 25075567
Background: Ipilimumab is an approved anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody introducing immune responses in melanoma patients. Treatment experiences from named-patient programs support the evaluation of the efficacy and tolerability of...
8.
9.
Al Ghazal P, Gutzmer R, Satzger I, Starz H, Bader C, Thoms K, et al.
Melanoma Res
. 2013 Dec;
24(2):158-64.
PMID: 24346168
Head or neck location of primary cutaneous melanomas has been described as an adverse prognostic factor, but this has to be reassessed after the introduction of sentinel lymph node (SLN)...
10.
Starz H, Gutschi M, Welzel J, Haas C
J Dtsch Dermatol Ges
. 2013 Nov;
12(2):151-4.
PMID: 24238398
No abstract available.